Alabama Medicaid spending on GLP-1 drugs

How much did Alabama Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $72.3 million for GLP-1 drugs paid through Alabama Medicaid in 2025, across at least 71,831 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 57 rows of 171, so these figures are floors.

Pharmacies were reimbursed at least $22.6 million for GLP-1 drugs paid through Alabama Medicaid in 2026 (quarter 1 only, as posted so far), across at least 21,926 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 14 rows of 47, so these figures are floors.

By year and ingredient

2020at least $2,392,925No data$3,712,959at least $6,043,411at least $793,323$92,930$214,231at least $13,249,779
2021at least $4,789,991No data$4,766,618at least $15,440,664at least $549,786$132,511$187,759at least $25,867,330
2022at least $8,478,433at least $434,878$4,056,548at least $28,650,362at least $272,415$120,642$155,858at least $42,169,136
2023at least $13,959,622at least $7,739,178$5,342,949at least $32,490,837at least $239,788$68,147$88,094at least $59,928,616
2024at least $25,286,549at least $15,416,470$1,761,246at least $22,521,965at least $79,689at least $45,832at least $50,382at least $65,162,133
2025at least $35,752,681at least $21,116,325at least $478,863at least $14,916,166at least $24,833$45,817Suppressedat least $72,334,685
2026 (Q1)at least $10,607,234at least $8,525,401at least $58,269at least $3,410,294No dataSuppressedSuppressedat least $22,601,198

By product, 2025

Ozempicat least $32,795,306at least 32,9676 of 18
Rybelsus$2,385,9722,4070 of 12
Wegovyat least $571,403at least 4287 of 19
Mounjaroat least $19,980,125at least 18,7616 of 30
Zepboundat least $1,136,201at least 1,0434 of 16
Liraglutide (generic name listing)at least $383,825at least 72011 of 24
Victozaat least $95,038at least 1561 of 8
Trulicityat least $14,916,166at least 15,26113 of 29
Bydureonat least $24,833at least 292 of 4
ByettaSuppressedSuppressed3 of 3
Soliqua$45,817590 of 4
XultophySuppressedSuppressed4 of 4

By quarter, 2025

Q1 2025at least $18,421,164at least 18,58716 of 41
Q2 2025at least $18,232,038at least 18,14215 of 43
Q3 2025at least $16,956,834at least 16,72215 of 43
Q4 2025at least $18,724,650at least 18,38011 of 44

By quarter, 2026 (posted so far)

Q1 2026at least $22,601,198at least 21,92614 of 47

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.